Novavax (NVAX) could be a great long-term investment
What’s up with Novavax?
Novavax (NVAX) opened at $48.20, which means the stock is down 6% from yesterday’s closing price of 48.17. Today, the company has a high of $48.84 and a low of $40.98. The company has a market cap of $2.64 billion with a 52-week high of $61.50 and a 52-week low of $3.54.
What about the future for Novavax?
The high forecast for Novavax is $50.00 while the low is $38.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Novavax has a weak forecast. A weak forecast is due to the company posting consistent losses in their earning reports. The future outlook does not seem too bright as this could potentially cause the company to file for bankruptcy. Based on this information NVAX seems to be a risky buy.
Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm’s vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.